Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Paraproteinemias 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 12Bortezomib 9Lenalidomide 6Cyclophosphamide 5isatuximab 3fludarabine 3daratumumab 3Granulocyte Colony-Stimulating Factor 3pomalidomide 2filanesib 2dacetuzumab 2Tacrolimus 2Steroids 2Injections, Subcutaneous 2Filgrastim 2Clinical Protocols 2Calcium Dobesilate 2Alemtuzumab 2plerixafor 1nirogacestat 1fludarabine phosphate 1ficlatuzumab 1birtamimab 1Zoledronic Acid 1Whole-Body Irradiation 1Vorinostat 1Tissue Banks 1Thalidomide 1Stem Cell Transplantation 1Ranitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraproteinemias × Tissue Banks × Plasma cell × Clear all
NCT01408225 2026-03-23

B-SCR-MM

Ohio State University Comprehensive Cancer Center

Recruiting
5,000 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡